Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports

MLA

David T.W. Wong, et al. “Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.” Frontiers in Oncology, vol. 10, July 2020. EBSCOhost, https://doi.org/10.3389/fonc.2020.01240/full.

APA

David T.W. Wong, Leah Ye, Chul Kim, Ning Li, Feng Li, David Chia, Fang Wei, Udayan Guha, & Jordan Cheng. (2020). Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.01240/full

Chicago

David T.W. Wong, Leah Ye, Chul Kim, Ning Li, Feng Li, David Chia, Fang Wei, Udayan Guha, and Jordan Cheng. 2020. “Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.” Frontiers in Oncology 10 (July). doi:10.3389/fonc.2020.01240/full.